The Treat and Reduce Obesity Act of 2025 would amend the Medicare statute to expand access to obesity prevention and treatment services. It authorizes Medicare coverage of intensive behavioral therapy for obesity when furnished not only by primary care physicians and practitioners, but also by other clinicians such as physician assistants, nurse practitioners, clinical nurse specialists, clinical psychologists, registered dietitians, nutrition professionals, and approved community-based lifestyle counseling programs, so long as the services are coordinated with a referring physician or primary care practitioner and provided in approved settings.
The bill also changes Medicare Part D to permit coverage of obesity medications and certain weight-loss management drugs for beneficiaries who are overweight and have at least one related comorbidity. Those drug coverage changes would take effect for plan years beginning two years after enactment. In addition, the bill requires the Secretary of Health and Human Services to report to Congress within one year of enactment, and every two years thereafter, on implementation and on opportunities to better coordinate federal programs related to obesity research, prevention, and treatment.
Impact
If enacted, the bill would amend Title XVIII of the Social Security Act and directly affect Medicare coverage rules. It would broaden the categories of providers eligible to furnish reimbursable intensive behavioral therapy for obesity and would create a pathway for Medicare Part D coverage of obesity-related medications and weight-loss management drugs for certain beneficiaries. The bill would also impose ongoing reporting obligations on HHS and could influence how federal obesity-related programs are coordinated across agencies.
Sentiment
Based on the bill text and available context, the overall sentiment appears supportive and policy-oriented, with the bill framed as a response to the growing prevalence and cost of obesity among Medicare beneficiaries. The findings emphasize obesity’s health risks, mortality impact, and rising Medicare spending, suggesting a strong public-health rationale for the proposal. There are no recorded committee transcripts or votes in the provided context, so no formal opposition or support beyond the bipartisan introduction can be assessed from the available materials.
Contention
The main policy issues likely to draw attention are Medicare spending, the scope of provider eligibility, and whether Part D should cover obesity drugs and weight-loss management medications. Supporters are likely to favor broader access to treatment, especially for older adults with multiple chronic conditions, while critics may question cost, long-term effectiveness, or whether medication coverage could expand utilization beyond intended medical need. Another possible point of debate is the requirement that non-physician therapy be coordinated with a physician or primary care practitioner, which balances expanded access with oversight.
To direct the Secretary of Defense to develop a strategy to treat obesity as a disease and reduce the prevalence of obesity in certain Armed Forces, and for other purposes.